Le Lézard
Classified in: Health
Subject: ACC

Body Vision Medical Announces $8.5 Million in Funding


RAMAT HA SHARON, Israel, Sept. 4, 2018 /PRNewswire/ ? Body Vision Medical, a medical device company specializing in lung cancer diagnostics through augmented real-time intra-body navigation and imaging, announced today $8.5 million in funding.  The proceeds will be used to accelerate the commercialization efforts of its FDA approved LungVisiontm system in the U.S. and to extend its product line.

Body Vision logo

"The LungVisiontm system introduces a novel real-time imaging tool to the bronchoscopy suite," said Dorian Averbuch, founder and CEO of Body Vision Medical. "Today, in order to diagnose small peripheral lesions, the pulmonologist has to use several different imaging modalities such as computerized tomography (CT), ultrasound (US) and fluoroscopy. Each of these modalities has advantages and disadvantages; however, even a combination of all of the above was unable to improve significantly a poor diagnostic yield of small peripheral lung lesions. For the first time, our fusion imaging platform enables the pulmonologist to use all the existing imaging modalities together, in real time, without changing or affecting the procedural flow. The LungVisiontm system, together with our unique delivery device, enables the physician to plan the procedure, navigate to challenging locations and localize the lesion during biopsy. This complete solution will facilitate early stage diagnosis of lung cancer and, in addition, will pave the way for minimally invasive transcatheter therapeutics."

Mr. Zohar Gilon, the Chairman of the company's Board, who led the financing round said: "It's been an immaculate journey to observe and support the company from the concept phase to where it is today, having two systems cleared by the FDA and solid clinical data from 400 patients in leading centers in the U.S."  Mr. Gilon continued, "From the very start we believed that the company was tackling substantial unmet needs utilizing a very novel and very promising approach. Dorian and his world-class team will save a great number of lives, and almost as important, decrease and shorten many families' pain and suffering. I was privileged to lead the financing of Body Vision from inception, and I was honored by about 20 of Israel's leading tech entrepreneurs and investors who joined me."

About Body Vision Medical
Body Vision Medical is a software and medical device company specializing in augmented real-time fusion imaging, artificial intelligence and intra-body navigation. The company was founded in 2014 to address the contemporary unfulfilled clinical need of early lung cancer diagnostics and treatment. To learn more about the company visit us at www.bodyvisionmedical.com.

Contact:
[email protected]
+1-646-863-7848

 

SOURCE Body Vision Medical


These press releases may also interest you

at 03:05
Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK's National Institute for Health and Care Excellence (NICE) has recommended the expanded use of the Oncotype DX Breast Recurrence Score® test to...

at 03:00
Charging an electric vehicle (EV) at home is certainly more convenient than using a public charging station, but what are the other benefits? Along with convenience, the...

at 02:15
Announces co-exclusive licensing agreement with Sanofi to co-commercialize COVID-19 vaccine, develop novel COVID-19-Influenza combination vaccines and develop multiple new vaccines utilizing Novavax's Matrix-MTM adjuvantThis agreement represents a...

at 02:05
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") and Maze Therapeutics, Inc. (Head Office: South San Francisco, California, USA; Chief Executive Officer: Jason Coloma, Ph.D.;...

at 02:00
Agreement provides individuals with broader access to a protein-based non-mRNA adjuvanted COVID-19 vaccine through combined commercial strength, from 2025 onwardsProvides Novavax with cash and an equity investment totalling approximately $1.2 billion...

at 01:00
REGULATED INFORMATIONMay 10, 2024, 7:00am CET / 1:00am ET NYXOAH SA(Euronext Brussels: NYXH) Rue Edouard Belin 12, 1435 Mont-Saint-Guibert, Belgium(hereinafter the "Company") Invitation to attend the annual and the extraordinary shareholders'...



News published on and distributed by: